About

About
The DS management team has both a strong background in developing drugs for the market and experience in building life science companies.

Pipeline

Pipeline
DS Biopharma have three novel assets in various stages of clinical and pre-clinical development and intend to add more bioactive lipids to the current portfolio in the coming years.

Investors

Investors
To date, DS Biopharma have been funded privately.

Latest News

May 23, 2016

DS Biopharma announces DS102 will be developed for pulmonary disorders in addition to NASH

DS Biopharma announces DS102 will be developed for pulmonary disorders in addition to NASH Dublin, Ireland, 23rd May, 2016: DS Biopharma (DS) today announced plans to […]
April 14, 2016

DS Biopharma presents late-breaking news abstract on DS102 at the European Association for the Study of the Liver (EASL) International Liver Congress

Dublin, Ireland, 14th April 2016: DS Biopharma (DS) is today presenting a late-breaking news abstract at the annual meeting of the EASL International Liver Congress in […]

Join our mailing list

Connect with us